These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 9733674)
41. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice. Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097 [TBL] [Abstract][Full Text] [Related]
42. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. Stamatovic SM; Shakui P; Keep RF; Moore BB; Kunkel SL; Van Rooijen N; Andjelkovic AV J Cereb Blood Flow Metab; 2005 May; 25(5):593-606. PubMed ID: 15689955 [TBL] [Abstract][Full Text] [Related]
43. Transport of [125I]transferrin through the rat blood-brain barrier. Skarlatos S; Yoshikawa T; Pardridge WM Brain Res; 1995 Jun; 683(2):164-71. PubMed ID: 7552351 [TBL] [Abstract][Full Text] [Related]
44. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Saito Y; Buciak J; Yang J; Pardridge WM Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757 [TBL] [Abstract][Full Text] [Related]
45. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26. Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883 [TBL] [Abstract][Full Text] [Related]
46. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Zhang Y; Pardridge WM Brain Res; 2006 Sep; 1111(1):227-9. PubMed ID: 16884698 [TBL] [Abstract][Full Text] [Related]
47. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349 [TBL] [Abstract][Full Text] [Related]
48. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. Zhang Y; Boado RJ; Pardridge WM J Gene Med; 2003 Dec; 5(12):1039-45. PubMed ID: 14661179 [TBL] [Abstract][Full Text] [Related]
49. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis. Chang HY; Wu S; Li Y; Zhang W; Burrell M; Webster CI; Shah DK MAbs; 2021; 13(1):1874121. PubMed ID: 33499723 [TBL] [Abstract][Full Text] [Related]
50. Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion. Alata W; Paris-Robidas S; Emond V; Bourasset F; Calon F Mol Pharm; 2014 Jan; 11(1):243-53. PubMed ID: 24215184 [TBL] [Abstract][Full Text] [Related]
51. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Zhang Y; Calon F; Zhu C; Boado RJ; Pardridge WM Hum Gene Ther; 2003 Jan; 14(1):1-12. PubMed ID: 12573054 [TBL] [Abstract][Full Text] [Related]
52. Neuroprotection with noninvasive neurotrophin delivery to the brain. Wu D; Pardridge WM Proc Natl Acad Sci U S A; 1999 Jan; 96(1):254-9. PubMed ID: 9874805 [TBL] [Abstract][Full Text] [Related]
53. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Boado RJ; Zhang Y; Wang Y; Pardridge WM Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151 [TBL] [Abstract][Full Text] [Related]
54. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Pardridge WM; Boado RJ Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573 [TBL] [Abstract][Full Text] [Related]
55. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664 [TBL] [Abstract][Full Text] [Related]
56. Noninvasive gene targeting to the brain. Shi N; Pardridge WM Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7567-72. PubMed ID: 10840060 [TBL] [Abstract][Full Text] [Related]
57. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. Bickel U; Kang YS; Yoshikawa T; Pardridge WM J Histochem Cytochem; 1994 Nov; 42(11):1493-7. PubMed ID: 7930531 [TBL] [Abstract][Full Text] [Related]
58. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity. Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588 [TBL] [Abstract][Full Text] [Related]
59. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Boado RJ; Zhang Y; Zhang Y; Pardridge WM Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408 [TBL] [Abstract][Full Text] [Related]
60. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Zhang Y; Pardridge WM Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]